Search: WFRF:(Evans Marc)
> (2015-2019) >
The value of mainta...
The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
-
- Evans, Marc (author)
- Llandough Hosp, Diabet Resource Ctr, Cardiff, S Glam, Wales
-
- Palaka, Eirini (author)
- AstraZeneca, Global Hlth Econ, Cambridge, England
-
- Furuland, Hans (author)
- Uppsala universitet,Njurmedicin
-
show more...
-
- Bennett, Hayley (author)
- Hlth Econ & Outcomes Res Ltd, Cardiff, S Glam, Wales
-
- Linde, Cecilia (author)
- Karolinska Institutet
-
- Qin, Lei (author)
- AstraZeneca, Global Hlth Econ, Gaithersburg, MD USA
-
- McEwan, Phil (author)
- Hlth Econ & Outcomes Res Ltd, Cardiff, S Glam, Wales;Swansea Univ, Sch Human & Hlth Sci, Swansea, W Glam, Wales
-
- Bakhai, Ameet (author)
- Royal Free Hosp, Dept Cardiol, London, England
-
show less...
-
(creator_code:org_t)
- 2019-01-31
- 2019
- English.
-
In: BMC Nephrology. - : Springer Science and Business Media LLC. - 1471-2369. ; 20
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- BackgroundPeople with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining kidney function. In addition, these patients are often required to reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) therapy due to increased risk of hyperkalaemia. This original research developed a model to quantify the health and economic benefits of maintaining normokalaemia and enabling optimal RAASi therapy in patients with CKD.MethodsA patient-level simulation model was designed to fully characterise the natural history of CKD over a lifetime horizon, and predict the associations between serum potassium levels, RAASi use and long-term outcomes based on published literature. The clinical and economic benefits of maintaining sustained potassium levels and therefore avoiding RAASi discontinuation in CKD patients were demonstrated using illustrative, sensitivity and scenario analyses.ResultsInternal and external validation exercises confirmed the predictive capability of the model. Sustained potassium management and ongoing RAASi therapy were associated with longer life expectancy (+ 2.36 years), delayed onset of end stage renal disease (+ 5.4 years), quality-adjusted life-year gains (+ 1.02 QALYs), cost savings (£3135) and associated net monetary benefit (£23,446 at £20,000 per QALY gained) compared to an absence of RAASi to prevent hyperkalaemia.ConclusionThis model represents a novel approach to predicting the long-term benefits of maintaining normokalaemia and enabling optimal RAASi therapy in patients with CKD, irrespective of the strategy used to achieve this target, which may support decision making in healthcare.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Keyword
- Chronic kidney disease
- Potassium
- Hyperkalaemia
- Renin-angiotensin-aldosterone system inhibitor
- Economic modelling
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database